Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Coherus BioSciences, Inc. (CHRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Unregistered Sales of Equity Securities  Interactive Data
10/06/2023 SC 13G/A BlackRock Inc. reports a 10.9% stake in COHERUS BIOSCIENCES INC
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/26/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/24/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
07/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/20/2023 8-K Quarterly results
07/07/2023 S-4 Form S-4 - Registration of securities, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Agreement and Plan of Merger, by and among Coherus BioSciences, Inc., Crimson Merger Sub I, Inc., Crimson Merger Sub II, LLC and Surface Oncology, Inc., (Form of CVR Agreement included as Exhibit A thereto)",
"Coherus to Acquire Surface Oncology"
06/09/2023 4 Wahlstrom Mats (Director) has filed a Form 4 on Coherus BioSciences, Inc.
Txns: Granted 38,250 options to buy @ $5.38, valued at $205.8k
06/09/2023 4 STOLPER MARK (Director) has filed a Form 4 on Coherus BioSciences, Inc.
Txns: Granted 38,250 options to buy @ $5.38, valued at $205.8k
06/09/2023 4 Newcomer Lee Nisley (Director) has filed a Form 4 on Coherus BioSciences, Inc.
Txns: Granted 38,250 options to buy @ $5.38, valued at $205.8k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/09/2023 4 TZOUMAKAS KIMBERLY JO (Director) has filed a Form 4 on Coherus BioSciences, Inc.
Txns: Granted 38,250 options to buy @ $5.38, valued at $205.8k
06/09/2023 4 O'Donnell-Tormey Jill (Director) has filed a Form 4 on Coherus BioSciences, Inc.
Txns: Granted 38,250 options to buy @ $5.38, valued at $205.8k
06/09/2023 4 Newton Charles W. (Director) has filed a Form 4 on Coherus BioSciences, Inc.
Txns: Granted 38,250 options to buy @ $5.38, valued at $205.8k
05/31/2023 8-K Other Events  Interactive Data
05/19/2023 SC 13G CITADEL ADVISORS LLC reports a 6.2% stake in Coherus Biosciences, Inc.
05/18/2023 8-K Asset disposition
Docs: "Underwriting Agreement, among Coherus BioSciences, Inc. and J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
05/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/15/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy